Ipamorelin: The Complete Guide to the Selective Growth Hormone Secretagogue (2026)

If you've spent any time researching peptides for growth hormone optimization, you've almost certainly encountered ipamorelin. Alongside CJC-1295, it's become one of the most widely discussed compounds in clinical wellness, anti-aging, and performance research circles — and for good reason.

Ipamorelin stands apart from other growth hormone-releasing peptides (GHRPs) not because it produces the highest GH peak, but because it does something none of its predecessors could: it releases growth hormone selectively, without dragging cortisol, ACTH, or prolactin along for the ride. That distinction, established in the landmark 1998 paper by Raun et al. in the European Journal of Endocrinology, earned it the title of "the first selective growth hormone secretagogue" — a label that still holds.

This guide covers everything the current evidence tells us about ipamorelin: how it works at the receptor level, what benefits are mechanistically plausible, how to dose it, how it stacks with CJC-1295, how it compares to older GHRPs, and where it stands legally in 2026.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide — a five-amino-acid chain with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. It was developed in the late 1990s from research into GHRP-1 derivatives, and it belongs to the class of growth hormone secretagogues (GHS): compounds that stimulate GH release from the pituitary gland.

Unlike growth hormone itself, which is a large 191-amino-acid protein requiring complex biosynthesis, ipamorelin is a small, stable peptide that works by activating a receptor in the pituitary — triggering the body's own GH production rather than replacing it from outside.

Mechanism of Action: How Ipamorelin Releases Growth Hormone

Ipamorelin is a selective agonist at the Growth Hormone Secretagogue Receptor type 1a (GHS-R1a) — the same receptor activated by the endogenous hunger hormone ghrelin. GHS-R1a is densely expressed on somatotroph cells in the anterior pituitary, the cells responsible for storing and releasing GH.

The signal transduction cascade works like this:

1. Ipamorelin binds GHS-R1a on the somatotroph
2. The receptor couples to Gαq/11 protein
3. This activates phospholipase C (PLC)
4. PLC generates IP3 (inositol trisphosphate)
5. IP3 triggers calcium release from the endoplasmic reticulum
6. Elevated intracellular calcium drives exocytosis of pre-stored GH vesicles
7. Result: a sharp, pulsatile GH release from the pituitary

The GH peak occurs approximately 40–60 minutes post-injection, then returns to near-baseline within 3–6 hours. This pulsatile pattern closely mirrors physiological GH secretion — a meaningful distinction from exogenous recombinant GH, which creates sustained supraphysiological levels.

What Makes Ipamorelin Selective — and Why That Matters

This is the defining pharmacological feature of ipamorelin. Every other GHRP — GHRP-6, GHRP-2, Hexarelin — activates not only pituitary somatotrophs but also corticotroph cells (causing cortisol and ACTH release) and lactotroph cells (causing prolactin release).

Ipamorelin does not.

From Raun et al. (1998): "Ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation, and this lack of effect on ACTH and cortisol plasma levels was evident even at doses more than 200-fold higher than the ED50 for GH release."

FSH, LH, TSH, and prolactin were similarly unaffected at any tested dose. This clean hormonal profile is what places ipamorelin in a different category from its predecessors.

Benefits of Ipamorelin: What the Research Supports

The benefits profile of ipamorelin flows mechanistically from GH and downstream IGF-1 elevation. It's important to note that robust human randomized controlled trials specific to ipamorelin are limited — most evidence is preclinical or extrapolated from broader GH biology. With that caveat stated:

Muscle Growth and Body Composition

Growth hormone and IGF-1 promote protein synthesis and nitrogen retention in muscle tissue while simultaneously stimulating lipolysis in adipocytes. The net effect — lean mass gain concurrent with fat loss — is one of the primary reasons ipamorelin attracts interest from performance and anti-aging research contexts.

In preclinical models, ipamorelin's fat mass reduction was comparable to direct recombinant GH administration at equivalent timepoints, suggesting that pulsatile GH stimulation via GHS-R1a is sufficient to drive meaningful anabolic and lipolytic downstream signaling.

Fat Loss

GH is a potent lipolytic hormone — it activates hormone-sensitive lipase in adipose tissue, mobilizing stored triglycerides for use as fuel. Because ipamorelin doesn't elevate cortisol (unlike GHRP-6), it avoids the cortisol-driven fat deposition that can partially offset GH-mediated lipolysis in older GHRPs.

Recovery and Tissue Repair

GH and IGF-1 stimulate fibroblast proliferation and collagen synthesis — the core mechanisms behind connective tissue repair, tendon healing, and post-exercise recovery. Accelerated recovery between training sessions is among the most consistently reported subjective benefits in wellness clinic settings.

Sleep Quality

GH secretion is physiologically tied to slow-wave (deep) sleep — the largest natural GH pulse occurs in the first hours after sleep onset. Improved sleep quality is typically the earliest reported benefit from ipamorelin protocols, often appearing within 1–2 weeks. The relationship is bidirectional: GH supports deep sleep architecture, and improved deep sleep further amplifies natural GH secretion.

Anti-Aging Effects

Age-related decline in GH secretion (somatopause) is associated with increased adiposity, reduced muscle mass, reduced bone mineral density, skin thinning, and impaired cognitive function. By restoring more youthful GH pulse amplitude, ipamorelin may counteract several aspects of somatopause. Improved skin elasticity, collagen density, and bone support are mechanistically downstream of GH/IGF-1 signaling via osteoblast activation.

Expected Timeline

• Weeks 1–2: Improved sleep depth, increased energy
• Weeks 4–8: Enhanced recovery, early body composition changes
• Months 3–6: More pronounced lean mass gain, fat loss, and skin improvements

Ipamorelin Dosing Protocols

No FDA-approved dosing exists for ipamorelin. The following protocols reflect clinical wellness and research settings.

Standard Dose Range

The most commonly cited dose is 100–300 mcg per injection, with 200 mcg serving as the standard reference point. Most protocols start at 100 mcg/day and titrate upward over 1–2 weeks.

Frequency and Timing

• Once daily (minimum): Pre-sleep injection, 30–45 minutes before bed, at least 2–3 hours after the last meal. This timing capitalizes on the natural nocturnal GH pulse and avoids blunting from elevated insulin.
• Twice daily: Morning (fasted) + pre-sleep. A common protocol for more active research applications.
• Three times daily: Pre-workout, afternoon, and pre-sleep. Used in higher-intensity protocols.

Critical timing note: Elevated insulin from recent meals significantly blunts GH release. Always inject on an empty stomach.

Cycling

• Standard: 8–12 weeks on, 4 weeks off
• Conservative: 3 months on, 1 month off (~3 cycles/year)

Cycling prevents GHS-R1a desensitization and maintains receptor sensitivity. Unlike exogenous recombinant GH, ipamorelin doesn't suppress endogenous GH production, so there's no suppression-rebound effect upon stopping.

Ipamorelin + CJC-1295: The Most Popular Peptide Stack

The CJC-1295 + Ipamorelin combination is the most widely discussed peptide stack in clinical wellness and research contexts — and the synergy is mechanistically well-founded.

Why the Stack Works

GH secretion relies on two complementary hypothalamic signals:

1. GHRH (Growth Hormone-Releasing Hormone) acts on the GHRH receptor on somatotrophs, activating adenylyl cyclase via Gαs → increasing cAMP → amplifying GH pulse amplitude and duration
2. Ghrelin/GHRPs act on GHS-R1a via the Gαq/11 → PLC → IP3 → calcium pathway, triggering GH exocytosis

CJC-1295 targets pathway #1. Ipamorelin targets pathway #2. The two signals converge on the same somatotroph cell through entirely different intracellular cascades — making them additive to synergistic rather than redundant.

The resulting GH pulse when both pathways are activated simultaneously is estimated to be 3–5x greater than from GHRH stimulation alone. Early research by Bowers et al. demonstrated that combined GHRH + GHRP-6 produced GH peaks 2–3x higher than either peptide alone — the same synergistic mechanism applies here.

Which Form of CJC-1295?

• CJC-1295 without DAC (MOD-GRF 1-29): Half-life ~30 minutes; closely matched to ipamorelin's pharmacokinetics; can be co-administered in the same syringe for practical, pulsatile dosing.
• CJC-1295 with DAC: Half-life extended to 7–8 days via albumin binding; weekly dosing; creates a sustained GH elevation rather than discrete pulses. Some researchers prefer the no-DAC form for more physiological pulsatility.

Stack Protocol (CJC-1295 No-DAC + Ipamorelin)

• Dose: 200–300 mcg of each per injection
• Frequency: 1–3x daily; pre-sleep is the priority injection
• Administration: Both can be drawn into the same insulin syringe — they're chemically compatible
• Cycle: 8–12 weeks on, 4 weeks off

Ipamorelin Side Effects and Safety

Ipamorelin's side effect profile is generally considered favorable compared to other GHRPs, primarily because of its hormonal selectivity.

Commonly Reported Side Effects

• Headaches: The most common systemic side effect; usually dose-dependent and transient, subsiding as the body adjusts
• Injection site reactions: Mild redness, itching, or swelling; typically resolve within hours
• Nausea: At higher doses; typically mild
• Temporary fatigue or drowsiness: Often linked to the initial GH pulse; considered a marker of activity rather than a concern
• Increased appetite: Milder than GHRP-6; ipamorelin's ghrelin mimicry is selective enough that strong hunger isn't reliably induced

Less Common / Higher-Dose Effects

• Water retention: A GH-class effect; typically mild and resolves
• Joint discomfort: Related to fluid shifts; dose-dependent
• Tingling or numbness: Carpal tunnel-adjacent symptoms from fluid retention
• Transient insulin sensitivity changes: GH is physiologically insulin-antagonistic; relevant for individuals with blood sugar concerns

Ipamorelin vs. GHRP-6, GHRP-2, and Hexarelin

All four compounds act as GHS-R1a agonists. The differences lie in selectivity, potency, and the side-effect burden they carry.

GHRP-6 is the historical benchmark — comparable GH potency to ipamorelin but with strong appetite stimulation (a significant compliance issue), meaningful cortisol elevation, and a dirtier hormonal profile overall.

GHRP-2 is more potent than both, but produces the strongest cortisol and prolactin elevations in the class.

Hexarelin produces the highest GH amplitudes of the group but desensitizes fastest, has cardiac receptor activity with unknown long-term implications, and causes significant cortisol, ACTH, and prolactin elevation.

Ipamorelin sacrifices peak GH amplitude compared to GHRP-2 and Hexarelin, but delivers a clean hormonal profile, sustainable long-term use without rapid desensitization, minimal appetite disruption, and a GH pulse that closely mimics physiological pulsatility. For most protocols, the trade-off favors ipamorelin.

Reconstitution and Administration

Ipamorelin is supplied as lyophilized (freeze-dried) powder in sterile vials. It must be reconstituted before injection.

Reconstitution Steps

1. Gather supplies: ipamorelin vial, bacteriostatic water (BAC water), insulin syringe (29–31 gauge), alcohol swabs
2. Wipe both vial tops with an alcohol swab; allow to dry
3. For a 5mg vial: draw 2.5 mL BAC water → 2 mg/mL concentration; adjust to achieve your target dose conveniently
4. Inject BAC water slowly down the inner glass wall of the peptide vial — do not aim directly at the powder
5. Gently swirl until fully dissolved. Do NOT shake — this can damage the peptide structure
6. Solution should be clear and colorless; discard if cloudy or particulate

Reconstituted vials are stable refrigerated at 2–8°C for approximately 28–30 days. The benzyl alcohol in BAC water acts as a bacteriostatic preservative for multi-dose vials.

Legal and Regulatory Status in 2026

Ipamorelin has not received FDA approval for any human therapeutic indication. Its regulatory status in the United States has been in active flux:

• 2023: The FDA placed ipamorelin on its Category 2 list under 503A/503B compounding regulations, effectively barring licensed compounding pharmacies from preparing and dispensing it.
• February 2026: HHS Secretary Kennedy announced expectations that approximately 14 of the 19 restricted peptides — including ipamorelin — would return to Category 1 (compounding-permitted) status.
• April 2026: The FDA removed 12 peptides from Category 2. Ipamorelin was not among them. The Pharmacy Compounding Advisory Committee (PCAC) voted against ipamorelin in October 2024, creating additional regulatory headwinds. Its compounding status remains under review.

Ipamorelin is currently classified as a research chemical for laboratory and investigational use in the United States. It is also on the WADA Prohibited List as a growth hormone secretagogue, banned in regulated sport both in- and out-of-competition.

Conclusion: Is Ipamorelin the Right GHRP?

Ipamorelin's appeal comes down to a specific trade-off: it is not the most potent GH releaser in its class, but it is the most selective. By delivering a meaningful GH stimulus without the cortisol, prolactin, and appetite disruption that accompany older GHRPs, it offers a profile that's practical, sustainable, and compatible with body composition and recovery goals.

Its synergy with CJC-1295 — the most popular peptide stack for good mechanistic reason — amplifies that GH stimulus through a complementary pathway, making the combination more effective than either alone.

For researchers and clinicians exploring growth hormone optimization, ipamorelin's combination of validated mechanism, favorable selectivity, and manageable side-effect profile makes it a logical starting point. As with all research peptides, access, dosing, and use should be approached in the context of current regulatory guidance and with appropriate medical oversight.

Key reference: Raun K, Hansen BS, Johansen NL, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552–561. PMID: 9849822.